Oncology Companion Diagnostics Market Forecast 2020-2030

Along with revenue prediction for the overall world market, there are 3 segmentations of the Oncology Companion Diagnostics market, with forecasts for 2 products, , 5 technologies, 4 end users each forecasted at a global and regional level.

SKU: PHA0649 Category: Diagnostics Tags: PHA0649, PHA0741, PHA1027, PHA1076 Code: PHA0649Pages: 131

Download Sample Form

"*" indicates required fields

Name*

Company*

Designation*

Job Title

Industry

Email*

Phone*

Address*

This field is hidden when viewing the form

Report Title

This field is hidden when viewing the form

Sample url

← Back to category Diagnostics

Description

Where is the Oncology Companion Diagnostics market heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 220-page report provides 60 tables, 30 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Oncology Companion Diagnostics market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors

– You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players

– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 3 segmentations of the Oncology Companion Diagnostics market, with forecasts for 2 products, , 5 technologies, 4 end users each forecasted at a global and regional level.

Global Oncology Companion Diagnostics Market 2020-2030 is segmented on the basis of product, technology, end user, and geography.

Global Oncology Companion Diagnostics Market By Product:
– Assays, Kits, & Reagents
– Software & Technology

Global Oncology Companion Diagnostics Market By Technology:
– Polymerase Chain Reaction
– Next-Generation Sequencing
– in Situ Hybridization
– Immunohistochemistry
– Other

Global Oncology Companion Diagnostics Market By End user:
– Pharmaceutical & Biopharmaceutical Companies
– Reference Laboratories
– Contract Research Organizations
– Other

Global Oncology Companion Diagnostics Market By Region:

– North America
– U.S.
– Canada

– Europe
– Germany
– France
– UK
– Italy
– Netherlands
– Rest of Europe

– Asia Pacific
– India
– China
– Japan
– Rest of Asia Pacific

– Central & South America

– Middle East & Africa

Qualitative Analysis

– Industry overview
– Industry trends
– Market drivers and restraints
– Market size
– Growth prospects
– Porter’s analysis
– PESTEL analysis
– Key market opportunities prioritized
– Competitive landscape

– Company overview
– Financial performance
– Product benchmarking
– Latest strategic developments

How the Oncology Companion Diagnostics Market report helps you

In summary, our 200-page report provides you with the following knowledge:

– Revenue forecasts to 2030 for each of the above mentioned segments each forecasted at a global and regional level, growth of all segments on regional level helps to understand most lucrative type/application/technology/end use.

– Revenue forecasts to 2030 for 5 regional and 10 key national markets , the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Netherlands, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.

– Prospects for established firms and those seeking to enter the market, including company profiles for over 10 of the major companies involved in the Oncology Companion Diagnostics market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Oncology Companion Diagnostics market and leading companies. You will find data, trends and predictions.

Get our report today The Oncology Companion Diagnostics Market Forecast 2020-2030: Forecasts by Product (Assays, Kits, & Reagents, Software & Technology) By Technology (Polymerase Chain Reaction, In Situ Hybridization, Immunochemistry, Others),by End use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations, Others) and Geography.

The Oncology Companion Diagnostics Market 2020-2030 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the cancer industry.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1. Global Oncology Companion Diagnostics Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report Includes:
1.5. Who is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain

2. Introduction to Oncology Companion Diagnostics Market
2.1. Market definition
2.2. Scope & Segmentation
2.2.1. Product
2.2.2. Technology
2.2.3. End user
2.2.4. Regional Scope
2.3. Assumptions For The Study
2.4. List of Data Sources

3. Oncology Companion Diagnostics Market Dynamics
3.1. Introduction
3.2. Market dynamics
3.2.1. Market drivers
3.2.1.1. Increasing Global Incidence of Cancer
3.2.1.2. Growing Need for Targeted therapy
3.2.1.3. Advantages of Companion Diagnostics
3.2.2. Market restraints
3.2.2.1. High Cost
3.2.3. Market opportunities
3.2.3.1. Growing Number of Clinical Trials
3.2.4. Regulatory Framework & Reimbursement Scenario
3.2.4.1. Regulatory Framework
3.2.4.2. Reimbursement Scenario
3.3. Porters Five Forces Model
3.3.1. Bargaining power of buyer
3.3.1.1. Increasing number of cancer patients
3.3.1.2. Companion diagnostics information availability
3.3.2. Bargaining power of supplier
3.3.2.1. Limited number of centers
3.3.2.2. Requirement for highly qualified professionals
3.3.3. Threat of substitutes
3.3.3.1. Buyer propensity to substitute
3.3.3.2. Switching cost
3.3.4. Threat of new entrants
3.3.4.1. Capital requirement
3.3.4.2. Stringent regulatory scenario
3.3.5. Industry rivalry
3.3.5.1. Exit barriers
3.3.5.2. Concentration rate
3.4. Recent Trends & Advancements
3.4.1. Product trends
3.4.2. Technology trends
3.5. SWOT Analysis
3.5.1. Strength
3.5.1.1. Highly difficult to cure characteristic of cancer
3.5.1.2. Long duration of treatment
3.5.2. Weakness
3.5.2.1. Limited number of service providers
3.5.2.2. Low penetration rate in Asian countries
3.5.3. Opportunities
3.5.3.1. India
3.5.3.2. China
3.5.3.3. japan
3.5.4. Threats
3.5.4.1. Alternate detection techniques
3.6. Mergers and Acquisitions
3.7. Entry of New Market Players
3.8. Cancer statistics by country
3.8.1. US
3.8.2. Canada
3.8.3. Mexico
3.8.4. Germany
3.8.5. UK
3.8.6. China
3.8.7. India
3.8.8. Japan
3.8.9. Italy
3.8.10. Spain
3.9. Cancer prevalence by type
3.9.1. Breast
3.9.2. Lung
3.9.3. Blood
3.9.4. Prostate
3.9.5. Skin
3.9.6. Stomach

4. Oncology Companion Diagnostics Market By Product 2020-2030
4.1. 4. Oncology Companion Diagnostics Market, Annual Growth Rate Comparison, By Product
4.2. 4. Oncology Companion Diagnostics Market, Market Share Comparison, By Product (2020 & 2030)
4.3. 4. Oncology Companion Diagnostics Market Size and Forecast, By Product
4.3.1. Assays, Kits, & Reagents Revenue Forecast 2020-2030
4.3.2. Software & Technology Revenue Forecast 2020-2030

5. Oncology Companion Diagnostics Market By Technology 2020-2030
5.1. 4. Oncology Companion Diagnostics Market, Annual Growth Rate Comparison, By Technology
5.2. 4. Oncology Companion Diagnostics Market, Market Share Comparison, By Technology (2020 & 2030)
5.3. 4. Oncology Companion Diagnostics Market Size and Forecast, By Technology
5.3.1. Polymerase Chain Reaction Revenue Forecast 2020-2030
5.3.2. Next-Generation Sequencing Revenue Forecast 2020-2030
5.3.3. in Situ Hybridization Revenue Forecast 2020-2030
5.3.4. Immunohistochemistry Revenue Forecast 2020-2030
5.3.5. Other Revenue Forecast 2020-2030

6. Oncology Companion Diagnostics Market By End User 2020-2030
6.1. 4. Oncology Companion Diagnostics Market, Annual Growth Rate Comparison, By End User
6.2. 4. Oncology Companion Diagnostics Market, Market Share Comparison, By End User(2020 & 2030)
6.3. 4. Oncology Companion Diagnostics Market Size and Forecast, By End User
6.3.1. Pharmaceutical & Biopharmaceutical Companies Revenue Forecast 2020-2030
6.3.2. Reference Laboratories Revenue Forecast 2020-2030
6.3.3. Contract Research Organizations Revenue Forecast 2020-2030
6.3.4. Other Revenue Forecast 2020-2030

7. Oncology Companion Diagnostics Market By Region 2020-2030
7.1. Global Oncology Companion Diagnostics Market, Annual Growth Rate Comparison, By Region
7.2. Global Oncology Companion Diagnostics Market, Market Share Comparison, By Region (2020 & 2030)
7.3. Global Oncology Companion Diagnostics Market Size and Forecast, By Region
7.4. North America Revenue Forecast 2020-2030
7.4.1. Market Size and Estimation by Product 2020-2030
7.4.2. Market Size and Estimation by Technology 2020-2030
7.4.3. Market Size and Estimation by End User 2020-2030
7.4.4. U.S. Revenue Forecast 2020-2030
7.4.4.1. Market Size and Estimation by Product 2020-2030
7.4.4.2. Market Size and Estimation by Technology 2020-2030
7.4.4.3. Market Size and Estimation by End User 2020-2030
7.4.5. Canada Revenue Forecast 2020-2030
7.4.5.1. Market Size and Estimation by Product 2020-2030
7.4.5.2. Market Size and Estimation by Technology 2020-2030
7.4.5.3. Market Size and Estimation by End User 2020-2030
7.5. Europe Revenue Forecast 2020-2030
7.5.1. Market Size and Estimation by Product 2020-2030
7.5.2. Market Size and Estimation by Technology 2020-2030
7.5.3. Market Size and Estimation by End User 2020-2030
7.5.4. Germany Revenue Forecast 2020-2030
7.5.4.1. Market Size and Estimation by Product 2020-2030
7.5.4.2. Market Size and Estimation by Technology 2020-2030
7.5.4.3. Market Size and Estimation by End User 2020-2030
7.5.5. UK Revenue Forecast 2020-2030
7.5.5.1. Market Size and Estimation by Product 2020-2030
7.5.5.2. Market Size and Estimation by Technology 2020-2030
7.5.5.3. Market Size and Estimation by End User 2020-2030
7.5.6. France Revenue Forecast 2020-2030
7.5.6.1. Market Size and Estimation by Product 2020-2030
7.5.6.2. Market Size and Estimation by Technology 2020-2030
7.5.6.3. Market Size and Estimation by End User 2020-2030
7.5.7. Italy Revenue Forecast 2020-2030
7.5.7.1. Market Size and Estimation by Product 2020-2030
7.5.7.2. Market Size and Estimation by Technology 2020-2030
7.5.7.3. Market Size and Estimation by End User 2020-2030
7.5.8. Netherlands Revenue Forecast 2020-2030
7.5.8.1. Market Size and Estimation by Product 2020-2030
7.5.8.2. Market Size and Estimation by Technology 2020-2030
7.5.8.3. Market Size and Estimation by End User 2020-2030
7.6. Asia Pacific Revenue Forecast 2020-2030
7.6.1. Market Size and Estimation by Product 2020-2030
7.6.2. Market Size and Estimation by Technology 2020-2030
7.6.3. Market Size and Estimation by End User 2020-2030
7.6.4. China Revenue Forecast 2020-2030
7.6.4.1. Market Size and Estimation by Product 2020-2030
7.6.4.2. Market Size and Estimation by Technology 2020-2030
7.6.4.3. Market Size and Estimation by End User 2020-2030
7.6.5. Japan Revenue Forecast 2020-2030
7.6.5.1. Market Size and Estimation by Product 2020-2030
7.6.5.2. Market Size and Estimation by Technology 2020-2030
7.6.5.3. Market Size and Estimation by End User 2020-2030
7.6.6. India Revenue Forecast 2020-2030
7.6.6.1. Market Size and Estimation by Product 2020-2030
7.6.6.2. Market Size and Estimation by Technology 2020-2030
7.6.6.3. Market Size and Estimation by End User 2020-2030
7.7. Central & South America Revenue Forecast 2020-2030
7.7.1. Market Size and Estimation by Product 2020-2030
7.7.2. Market Size and Estimation by Technology 2020-2030
7.7.3. Market Size and Estimation by End User 2020-2030
7.8. Middle East & Africa Revenue Forecast 2020-2030
7.8.1. Market Size and Estimation by Product 2020-2030
7.8.2. Market Size and Estimation by Technology 2020-2030
7.8.3. Market Size and Estimation by End User 2020-2030

8. Competitive Landscape
8.1. Agilent Technologies
8.1.1. Company overview
8.1.2. Product portfolio
8.1.3. Financial performance
8.1.4. Recent strategies
8.2. QIAGEN N.V.
8.2.1. Company overview
8.2.2. Product portfolio
8.2.3. Financial performance
8.2.4. Recent strategies
8.3. Abbott
8.3.1. Company overview
8.3.2. Product portfolio
8.3.3. Financial performance
8.3.4. Recent strategies
8.4. Almac Group
8.4.1. Company overview
8.4.2. Product portfolio
8.4.3. Financial performance
8.4.4. Recent strategies
8.5. Danaher Corporation
8.5.1. Company overview
8.5.2. Product portfolio
8.5.3. Financial performance
8.5.4. Recent strategies
8.6. Biomérieux SA
8.6.1. Company overview
8.6.2. Product portfolio
8.6.3. Financial performance
8.6.4. Recent strategies
8.7. Illumina Inc
8.7.1. Company overview
8.7.2. Product portfolio
8.7.3. Financial performance
8.7.4. Recent strategies
8.8. Thermo Fisher Scientific, Inc.
8.8.1. Company overview
8.8.2. Product portfolio
8.8.3. Financial performance
8.8.4. Recent strategies
8.9. Myriad Genetics, Inc
8.9.1. Company overview
8.9.2. Product portfolio
8.9.3. Financial performance
8.9.4. Recent strategies
8.10. Sysmex Corporation
8.10.1. Company overview
8.10.2. Product portfolio
8.10.3. Financial performance
8.10.4. Recent strategies
8.11. Abnova Corporation
8.11.1. Company overview
8.11.2. Product portfolio
8.11.3. Financial performance
8.11.4. Recent strategies
8.12. Guardant Health
8.12.1. Company overview
8.12.2. Product portfolio
8.12.3. Financial performance
8.12.4. Recent strategies
8.13.

9. Conclusions
9.1. Key Findings in The Oncology Companion Diagnostics Market
9.2. Recommendations for The Oncology Companion Diagnostics Market

10. Glossary

List of Tables:

1. Global Oncology Companion Diagnostics Market, 2020 & 2030 (USD Million)
2. North Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
3. North America Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
4. North America Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
5. U.S. Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
6. U.S. Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
7. U.S. Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
8. Canada Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
9. Canada Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
10. Canada Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
11. Europe Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
12. Europe Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
13. Europe Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
14. France Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
15. France Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
16. France Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
17. Germany Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
18. Germany Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
19. Germany Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
20. UK Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
21. UK Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
22. UK Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
23. Netherlands Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
24. Netherlands Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
25. Netherlands Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
26. Italy Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
27. Italy Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
28. Italy Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
29. Asia Pacific Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
30. Asia Pacific Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
31. Asia Pacific Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
32. China Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
33. China Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
34. China Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
35. India Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
36. India Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
37. India Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
38. Japan Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
39. Japan Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
40. Japan Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
41. Central & South America Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
42. Central & South America Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
43. Central & South America Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)
44. Middle East & Africa Oncology Companion Diagnostics Market, by product , 2020-2030 (USD Million)
45. Middle East & Africa Oncology Companion Diagnostics Market, by technology , 2020-2030 (USD Million)
46. Middle East & Africa Oncology Companion Diagnostics Market, by end user, 2020-2030 (USD Million)

List of Figures
1. Research Methodology
2. Market Size Estimation Methodology
3. Forecasting Methodology
4. Global Oncology Companion Diagnostics Market, impact analysis
5. SWOT Analysis
6. Global Oncology Companion Diagnostics Market, Company Market Share Analysis
7. Global Oncology Companion Diagnostics Market Segmentation
8. Global Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Product , 2020 & 2030
9. Global Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Technology , 2020-2030
10. Global Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by End user, 2020-2030
11. North America Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Product , 2020 & 2030
12. North America Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Technology , 2020-2030
13. North America Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by End user, 2020-2030
14. Europe Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Product , 2020 & 2030
15. Europe Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Technology , 2020-2030
16. Europe Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by End user, 2020-2030
17. Asia Pacific Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Product , 2020 & 2030
18. Asia Pacific Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Technology , 2020-2030
19. Asia Pacific Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by End user, 2020-2030
20. Central & South America Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Product , 2020 & 2030
21. Central & South America Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Technology , 2020-2030
22. Central & South America Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by End user, 2020-2030
23. Middle East & Africa Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Product , 2020 & 2030
24. Middle East & Africa Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Technology , 2020-2030
25. Middle East & Africa Oncology Companion Diagnostics Market Share and Y-o-Y Growth, by Se End user, 2020-2030

F. Hoffmann-La Roche AG
Almac Group
Danaher Corporation
Illumina Inc.
Biomérieux SA
Myriad Genetics, Inc.
Agilent Technologies, Inc.
QIAGEN N.V.
Abbott Laboratories, Inc.
Sysmex Corporation
Thermo Fisher Scientific, Inc.
Abnova Corporation
Guardant Health, Inc.